Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 539,600 shares, a decrease of 26.7% from the February 13th total of 736,300 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 4.4% of the company’s stock are short sold.

Cyclo Therapeutics Stock Down 3.4 %

Shares of Cyclo Therapeutics stock traded down $0.02 on Monday, reaching $0.68. The stock had a trading volume of 56,359 shares, compared to its average volume of 409,969. The stock has a market capitalization of $22.25 million, a P/E ratio of -0.75 and a beta of -0.57. Cyclo Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.79. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.73.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Two Sigma Securities LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.15% of Cyclo Therapeutics at the end of the most recent reporting period. 68.55% of the stock is currently owned by institutional investors and hedge funds.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.